Allergy Therapeutics PLC Directorate Change (6993G)
08 November 2018 - 6:01PM
UK Regulatory
TIDMAGY
RNS Number : 6993G
Allergy Therapeutics PLC
08 November 2018
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Directorate Change
8 November 2018 Allergy Therapeutics (AIM:AGY), the fully
integrated specialty pharmaceutical company specialising in allergy
vaccines, announces the appointment of Mr Scott Leinenweber to the
Company's Board as a Non-Executive Director, nominated by Abbott
Laboratories, Inc. ("Abbott", NYSE: ABT) in replacement of Mr Jeff
Barton who retires from the Board, both effective after close of
business 7 November 2018.
Scott Leinenweber currently serves as Vice President of Investor
Relations and Licensing & Acquisitions at Abbott. During his
time in this role, he has been the lead spokesman with investors
and served as lead for Abbott's M&A activities in the Medical
Devices, Diagnostics, Pharmaceuticals and Nutritionals business
segments. Scott started his career at Abbott as a financial analyst
in 1997, before moving into product management, sales and marketing
roles across Abbott's businesses. Mr Leinenweber holds a degree in
finance from the University of Wisconsin-Oshkosh and a Masters of
Business Administration from the Marquette University, Graduate
School of Business.
Peter Jensen, Chairman of Allergy Therapeutics, commented: "We
are pleased to welcome Scott to the Board. He brings extensive
investor relations and marketing experience, particularly in the
United States, which will be valuable to our Company as we continue
to execute our global strategy. We also wish to take this
opportunity to thank Jeff for his contribution and support to
Allergy Therapeutics since February 2017."
Scott Michael Leinenweber, aged 47, is, or has been, a director
or partner of the following companies or partnerships during the
past five years:
Current Directorships and Partnerships Past Directorships and Partnerships in the previous five
years
Abbott Healthcare Private Limited (an Indian subsidiary of None
Abbott Laboratories)
There are no further disclosures required in accordance with AIM
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies.
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Emma Earl, Corporate Finance
Erik Anderson, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia
Manser
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional fourteen
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved 10% compound annual
growth since formation, employs c.500 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUGGMGGUPRGRM
(END) Dow Jones Newswires
November 08, 2018 02:01 ET (07:01 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024